PDCD1 and neoplasm: Jiang et al. found that, under the induction of ES and CuCl2, the cGAS-STING activity in dendritic cells co-cultured with cuproptosis-activated ccRCC cells increased in a dose-dependent manner, and the combination of cuproptosis inducers (ES and CuCl2) and anti-PD-1 therapy can synergistically increase the levels of circulating CD45+, CD8+ T lymphocytes, enhance the pro-inflammatory response and the production of type I IFN, thereby amplifying the anti-tumor immune response and enhancing the efficacy of anti-PD-1 therapy (Jiang et al., 2022).